What is the FDA PCAC July 2026 hearing?

The FDA's Pharmacy Compounding Advisory Committee (PCAC) will meet July 23-24, 2026 at the FDA White Oak Campus in Silver Spring, Maryland to evaluate seven peptides — BPC-157, KPV, TB-500, MOTS-C, Emideltide (DSIP), Semax, and Epitalon — for possible inclusion on the Section 503A Bulk Drug Substances List. A positive PCAC recommendation would initiate the rulemaking process toward making these substances legally available for compounding under physician supervision.

How can I submit a public comment on the PCAC hearing?

Submit written comments electronically at regulations.gov under Docket No. FDA-2025-N-6895 by July 9, 2026. Comments submitted by this date will be provided to the committee before the meeting. The docket closes July 22, 2026. For oral presentations at the meeting, contact Takyiah Stevenson at PCAC@fda.hhs.gov by June 30, 2026.

What does a favorable PCAC recommendation actually mean for patients?

A favorable PCAC recommendation initiates FDA's formal rulemaking process to add the substance to the 503A Bulks List. This involves publishing a proposed rule, a public comment period, and a final rule — a process that typically takes many additional months. It does not immediately authorize compounding. It means the pathway is open and moving forward. Patients should not expect immediate access even following a favorable vote.

FDA PCAC July 2026 Hearing: What the Panel Will…

⚕️ Medical & Legal Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, legal counsel, or regulatory guidance. Nothing here should be interpreted as authorization to compound, prescribe, or use any substance discussed. Regulatory status is evolving — consult a licensed healthcare provider and qualified legal counsel before making clinical or business decisions based on this content.

TL;DR

The FDA's Pharmacy Compounding Advisory Committee (PCAC) meets July 23–24, 2026 to evaluate seven peptides for the 503A Bulk Drug Substances List.
On the agenda: BPC-157, KPV, TB-500, MOTS-C (July 23) and Emideltide (DSIP), Semax, Epitalon (July 24).
All seven were removed from Category 2 (the prohibited compounding category) effective April 23, 2026 — but that removal alone does not make them legal to compound.
This hearing is the most consequential regulatory event for compounded peptides since the 2023–2024 Category 2 restrictions.
Public comment deadline: July 9, 2026 at regulations.gov, Docket No. FDA-2025-N-6895.
A favorable PCAC recommendation opens the rulemaking door — it does not immediately restore compounding access.

On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee will convene at the White Oak Campus in Silver Spring, Maryland for the most consequential two-day peptide hearing in recent memory. The seven substances on the agenda — BPC-157, KPV, TB-500, MOTS-C, Emideltide, Semax, and Epitalon — represent the leading edge of what may become a formal restoration of the compounding pathway for some of the most discussed peptide therapies in functional and regenerative medicine.

This hearing didn't emerge from nowhere. It is the result of nearly three years of regulatory conflict, litigation, political pressure, and a change in administration. Understanding what the PCAC actually does, what this specific hearing will evaluate, and what each possible outcome means for patients and practitioners requires understanding how we got here.

What Is the PCAC — and Why Does Its Vote Matter?

The Pharmacy Compounding Advisory Committee is a federal advisory committee that provides scientific, technical, and medical recommendations to the FDA on issues related to Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act). The committee's role is to evaluate evidence submitted in support of petitioned substances and issue recommendations on whether those substances should be placed on the 503A Bulk Drug Substances List.

PCAC typically consists of scientific experts in pharmacology, toxicology, clinical medicine, and pharmacy. Meetings are open to the public. The FDA presents its own staff analysis, nominators present their case for each substance, and public commenters are allotted time during open sessions.

Advisory, Not Binding — But Weight Is Real

PCAC recommendations are advisory. The FDA is not legally required to follow them. However, in practice, PCAC recommendations carry substantial regulatory weight. A favorable recommendation initiates rulemaking toward 503A Bulks List inclusion. An unfavorable recommendation typically means the substance stays off the list — and based on historical pattern, FDA staff recommendations and PCAC votes have tracked closely.

The committee evaluates nominated substances on four main criteria:

Physical and chemical characterization — Is the substance well-characterized, stable, and suitable for pharmaceutical compounding?
Safety concerns — Are there known or plausible safety risks specific to compounding use?
Available evidence of effectiveness — What does the published literature show about the substance's efficacy for its nominated indication(s)?
Historical use in compounding — How has the substance been used, by whom, for what conditions, and what does the clinical literature say?

The question is explicitly not: "Is this substance safe and effective for general use?" It is: "Is this substance appropriate for inclusion in the 503A compounding framework?" That framing matters — it's narrower than full drug approval but still a meaningful evidentiary bar.

How We Got Here: The Category 2 Saga

Between September 2023 and December 2024, the prior FDA administration moved 19 widely used compounded peptides to Category 2 status on the interim 503A Bulk Drug Substances List. Category 2 designates substances that present "significant safety concerns" — effectively prohibiting their use in compounding under Section 503A.

The affected peptides included BPC-157, Thymosin alpha-1, CJC-1295, Ipamorelin, AOD-9604, Thymosin Beta-4, Semax, Epitalon, KPV, and MOTS-C, among others. For patients who had been receiving these therapies through licensed compounding pharmacies under physician supervision — for gut healing, immune support, injury recovery, and cognitive function — the restrictions effectively closed the regulated access pathway overnight.

Demand did not disappear. It shifted — directly into unregulated online vendors selling products labeled "research chemicals." Industry analyses have estimated that over 40% of peptide products from unregulated vendors contain inaccurate dosing, contamination, or degraded compounds. The restrictions made patient sourcing less visible, not less risky.

Several compounding pharmacy groups and industry associations challenged the Category 2 designations in litigation, arguing the FDA had bypassed legally required notice-and-comment procedures when making those designations. The legal pressure, combined with a change in administration, set the stage for what happened in April 2026.

The RFK Jr. Announcement and FDA's April 15 Action

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. publicly announced the current administration's intent to reverse the Category 2 peptide restrictions and restore the compounding pathway. That announcement signaled a change in regulatory posture, but was not itself a formal FDA action.

The formal action came on April 15, 2026, when the FDA published Federal Register notice FR Doc. 2026-07361 (Docket No. FDA-2025-N-6895). That notice did two things simultaneously:

Announced the removal of 11 peptides from Category 2, effective seven days from the notice date (April 23, 2026)
Confirmed the scheduling of a July 23–24, 2026 PCAC hearing to evaluate seven of those substances for 503A Bulks List inclusion

A further four substances — CJC-1295, Ipamorelin, Thymosin alpha-1, and GHK-Cu (injectable) — were also removed from Category 2 but are scheduled for a separate PCAC review before the end of February 2027. Their path to formal compounding eligibility has a longer regulatory runway.

Important: Removal from Category 2 Is Not Authorization to Compound

As of April 23, 2026, the seven peptides on the July PCAC agenda are no longer in the prohibited Category 2. However, they have not been added to the 503A Bulks List. They occupy a transitional status. The formal legal pathway for compounding these substances runs through PCAC review, FDA rulemaking, and final list placement — none of which have yet occurred. Facilities should consult compliance counsel before making operational decisions based on the April 15 update alone.

The Seven Peptides Under Review

The PCAC will evaluate each substance on its nominated therapeutic indication — not on the broader research landscape patients and practitioners are more familiar with. That distinction matters: a substance may have a strong scientific case for off-label uses that won't directly factor into the committee's evaluation, which is scoped to the nominated indication.

Day One: July 23, 2026

Peptide	Nominated Indication	Evidence Grade	Notes
BPC-157	Ulcerative colitis	Tier B	Extensive animal data; no completed human RCTs. Mechanism well-characterized. Historically the most widely compounded of the seven.
KPV	Wound healing and inflammatory conditions	Tier C	Alpha-MSH tripeptide fragment. Anti-inflammatory mechanism in mucosal tissue well-supported in preclinical models.
TB-500 (Thymosin Beta-4 fragment LKKTETQ)	Wound healing	Tier C	Fragment of the naturally occurring Thymosin Beta-4 protein. Actin-binding activity; tissue repair evidence largely preclinical.
MOTS-C	Obesity and osteoporosis	Tier C	Mitochondria-derived peptide with metabolic and bone-density signaling. Growing but early evidence base. High commercial interest given the GLP-1 market context.

Day Two: July 24, 2026

Peptide	Nominated Indication	Evidence Grade	Notes
Emideltide (DSIP)	Opioid withdrawal, chronic insomnia, narcolepsy	Tier C	Delta sleep-inducing peptide. Russian clinical literature exists but is not well-integrated into Western evidence standards.
Semax	Cerebral ischemia, migraine, trigeminal neuralgia	Tier C	ACTH-derived neuropeptide. Approved and widely used in Russia for neurological indications. Limited Western RCT data by FDA standards.
Epitalon	Insomnia	Tier C	Tetrapeptide from the Khavinson research lineage. Russian clinical data; published studies on telomere length and melatonin secretion. Evidence base largely outside FDA's standard review framework.

Evidence Tier Key

Tier A — Multiple well-designed human RCTs with consistent findings. Tier B — Some human data, case series, or strong mechanistic studies. Tier C — Primarily preclinical or non-Western clinical evidence. For deeper dives on specific peptides, see our guides on BPC-157 and KPV for gut healing, Semax, Epitalon, and MOTS-C.

A Closer Look at BPC-157: The Highest-Stakes Substance

BPC-157 (Body Protection Compound-157) is a 15-amino acid synthetic peptide derived from a naturally occurring gastric juice protein. It is the most widely prescribed and compounded peptide on the entire July agenda, and its outcome will be closely watched as a signal for how the others may be evaluated.

The evidence profile for BPC-157 is unusual: the preclinical literature is extensive and consistent — dozens of peer-reviewed studies in rodent and canine models demonstrating effects on gut healing, tendon and ligament repair, bone healing, and neuroprotection. The central weakness is the absence of completed human RCTs by Western regulatory standards. The compound's gut-healing properties are the best-evidenced applications, which is why the nominated indication (ulcerative colitis) plays to its strongest evidence base.

BPC-157's structural properties also make it a favorable compounding candidate from a safety perspective: it does not bind to known receptor systems implicated in major adverse effects, and animal safety data is reassuring even at high doses. Whether that evidence profile meets the PCAC's bar for a favorable recommendation is the central question.

For more on BPC-157's mechanism and clinical evidence, see our complete guide on BPC-157 and KPV for gut healing.

Historical PCAC Decisions on Peptides: What the Track Record Shows

The July 2026 hearing does not occur in a vacuum. PCAC has evaluated peptides before, and the outcomes have not been favorable.

Meeting	Peptides Reviewed	Outcome
December 4, 2024	Thymosin alpha-1, AOD-9604, CJC-1295	Voted AGAINST recommending for compounding. FDA staff presentation consumed ~3 hours per substance; nominators given ~15 minutes.
October 29, 2024	Ipamorelin, kisspeptin-10, l-theanine, ibutamoren	Voted AGAINST recommending for compounding across all substances.
June 8, 2022	Glutathione, ferric subsulfate, enclomiphene, ammonium tetrathiomolybdate	FDA proposed NOT to include all four. Mixed outcomes after committee discussion.

Several advocacy organizations have publicly criticized the PCAC process as structurally weighted against natural and compounded substances. The Alliance for Natural Health USA has called it a "rigged process" — noting that FDA staff typically receive hours to present the case against compounding, while nominators and advocates are given 15 minutes per substance to respond.

The July 2026 hearing differs from 2024 in one critical way: the current administration has publicly committed to a more permissive regulatory posture on compounded peptides, and RFK Jr.'s February 2026 statement reflected that explicitly. Whether that political context translates into different outcomes at the committee level — which is staffed by scientific experts evaluating evidence, not administering political direction — is the central unknown.

What the PCAC Process Actually Looks Like

Here is the structure of a typical PCAC meeting day for a substance under review:

FDA staff presentation: The Center for Drug Evaluation and Research presents its analysis of the substance — physical/chemical characterization, safety review, efficacy review, and historical compounding data. This portion typically dominates the session time.
Nominator presentations: Those who nominated the substance for the list present their case, including clinical evidence and safety arguments. Time is limited.
Open public hearing: Registered public speakers are given allotted time. Patient advocates, practitioners, and compounding pharmacy representatives typically use this session.
Committee discussion and vote: PCAC members deliberate and vote on whether to recommend the substance for inclusion on the 503A Bulks List.

At the July 2026 hearing, public sessions begin approximately 10:15 a.m. ET on July 23 and 10:20 a.m. ET on July 24. The meeting is open to the public in person at the FDA White Oak Campus and via virtual teleconferencing.

How to Submit Public Comments

This is a genuine opportunity to put patient experience and clinical data directly in front of the committee. Here is how to participate:

Participation Timeline

June 30, 2026: Deadline to request a speaking slot for oral presentations at the meeting. Contact Takyiah Stevenson at PCAC@fda.hhs.gov or 240-402-2507.
July 1, 2026: FDA notifies registered speakers of their allotted time (subject to lottery if demand exceeds capacity).
July 9, 2026: Deadline for written comments to be included in the committee's pre-meeting materials. Submit at regulations.gov, Docket No. FDA-2025-N-6895.
July 22, 2026: Docket closes. Late comments will not be considered by the committee.
July 23–24, 2026: PCAC meeting, FDA White Oak Campus, Silver Spring, Maryland. Virtual attendance available.

Writing a Comment That Gets Read

Written comments to FDA dockets are public record and are reviewed by committee members. Comments that carry the most weight are:

Specific about the substance — Address one peptide in your comment, not all seven.
Clinical or experiential — First-person patient accounts of benefit and safety, or practitioner case documentation, are harder to dismiss than opinion alone.
Grounded in the four PCAC criteria — If you can speak to safety, efficacy, compounding history, or chemical characterization, anchor your comment there.
Not duplicative — Identical form-letter comments carry less weight than individually written submissions.

Possible Outcomes and What Each Means for Patients

The PCAC can reach one of several conclusions for each substance. These outcomes have very different implications for access, pricing, and the legal landscape.

Outcome	What It Means	Timeline to Compounding Access
Favorable recommendation	PCAC recommends inclusion on the 503A Bulks List. FDA initiates rulemaking: proposed rule → public comment → final rule.	6–18 months post-hearing (rulemaking required). Access remains through licensed compounding pharmacies under physician supervision.
Conditional / data-limited recommendation	Committee finds the evidence promising but incomplete. May recommend deferral pending additional safety data or controlled studies.	Uncertain — substance enters extended review. Longer timeline, but door not closed.
Unfavorable recommendation	Committee finds insufficient evidence or unresolved safety concerns. FDA likely will not add substance to Bulks List. Substance effectively excluded from 503A compounding framework.	No near-term access through regulated pharmacy channel. Patients likely return to gray-market sourcing.

Gray Market Risk Remains Real

Regardless of PCAC outcomes, gray-market peptide vendors will continue operating. If the July hearing produces unfavorable outcomes, patient demand will not disappear — it will simply move further from regulated oversight. Industry analyses have estimated over 40% contamination or dosing error rates in unregulated peptide products. For patients evaluating sourcing options, the distinction between licensed compounding pharmacy and online research-use vendors is not cosmetic — it is a material safety question. See our guide to evaluated peptide providers and our analysis of what happens when compounding access closes.

What Outcomes Mean for Pricing and Practical Access

Favorable PCAC outcomes and eventual 503A Bulks List placement would mean:

For patients: Access through licensed pharmacies via prescription, with quality controls (sterility, potency verification, USP standards). Pricing typically $50–$200/month depending on peptide, dose, and pharmacy — substantially less than pharma alternatives for conditions like obesity or inflammation.
For practitioners: Clear legal footing for prescribing. Ability to document compounding source for patient records. Reduced liability exposure relative to gray-market recommendations.
For compounding pharmacies: Restoration of the 503A framework for these substances, with full USP compliance obligations. API suppliers are likely already preparing for this scenario.

Unfavorable outcomes would preserve the existing gray-market dynamic — higher safety risk, no physician oversight, and no quality assurance — while patients lose access to the regulated pharmacy channel.

Key Signals to Watch During the Hearing

If you're following the hearing in real time or reviewing transcripts afterward, here are the signals that indicate which way the committee is leaning for each substance:

FDA staff framing: Does the staff analysis lead with safety concerns as disqualifying, or does it present a balanced review? The 2024 hearings were characterized by FDA staff spending hours building the case against inclusion. A shorter or more balanced presentation is a better sign.
Committee questions to nominators: Are questions focused on closing evidentiary gaps (constructive) or on establishing disqualifying concerns (adversarial)?
Discussion of evidence standards: Does the committee acknowledge that absence of human RCT data reflects the cost and regulatory hurdle of clinical trials, not absence of safety and efficacy evidence?
Split votes: A close 7-6 or 8-5 vote against is very different from a unanimous rejection. Split votes signal that the evidence base is being taken seriously and that a different committee composition might produce a different outcome.
Conditions attached: A favorable recommendation with conditions (further safety data required) is a partial win — the pathway is open, but the rulemaking will take longer.

Broader Context: Why This Hearing Matters Beyond Seven Peptides

The July PCAC hearing is not just about BPC-157 and Semax. It is a test of whether the current regulatory posture will translate into actual changes in the 503A compounding framework — or whether the institutional PCAC process will produce the same outcomes as 2024 despite a different political environment.

The compounded peptide market serves patients who need patient-specific formulations, patients who cannot afford or cannot access brand-name alternatives, and patients whose conditions don't map cleanly onto the FDA-approved drug supply. The question this hearing ultimately answers is whether the 503A Bulks List will function as the legal mechanism those patients are supposed to be able to rely on — or whether it will continue to fail them, pushing access into channels that carry real, documented risks.

For broader regulatory context on what's happening with GLP-1 peptides and compounding access, see our reporting on the compounded semaglutide ban and what's still available for GLP-1 compounding in 2026. For context on the peptide delivery landscape, see our complete guide to peptide delivery methods.

Frequently Asked Questions

What is the FDA PCAC and why should patients care about its July 2026 meeting?

The Pharmacy Compounding Advisory Committee (PCAC) advises the FDA on which drug substances can be legally used by compounding pharmacies under Section 503A. Its July 23–24, 2026 meeting will evaluate seven widely used peptides — BPC-157, KPV, TB-500, MOTS-C, Emideltide, Semax, and Epitalon — for inclusion on the 503A Bulk Drug Substances List. If included, these peptides can be compounded by licensed pharmacists and dispensed to patients with a valid prescription. If excluded, the regulated compounding pathway closes for those substances, leaving patients with only unregulated gray-market sources or commercial alternatives (where they exist). For anyone using or considering these peptides, this hearing directly shapes what legal, quality-controlled access looks like going forward.

Can I still get BPC-157 or Semax from a compounding pharmacy right now?

As of April 23, 2026, BPC-157, Semax, and the five other peptides on the July agenda were removed from Category 2 (the prohibited compounding category). However, removal from Category 2 is not the same as being added to the 503A Bulks List — which is the formal legal authorization for compounding. These substances exist in a transitional regulatory status: no longer formally prohibited, but not yet formally authorized. The FDA's enforcement posture during this transitional window matters, and facilities should consult compliance counsel. Patients should work with licensed providers rather than assuming current availability across all pharmacy and prescribing contexts.

How do I submit a public comment to the FDA about this hearing?

Go to regulations.gov and search for Docket No. FDA-2025-N-6895. Submit your written comment electronically. Comments must be received by July 9, 2026 to be included in the materials provided to the committee before the meeting. The docket remains open through July 22, 2026, but comments received after July 9 will not be in the committee's pre-meeting packet. For oral presentations at the meeting itself, contact Takyiah Stevenson at PCAC@fda.hhs.gov or 240-402-2507 by June 30, 2026. Meaningful, individual comments — particularly from patients with documented clinical experience or practitioners with case data — carry more weight than form-letter submissions.

What happened at previous PCAC meetings on peptides?

The track record is not favorable. At the December 2024 meeting, PCAC voted against recommending Thymosin alpha-1, AOD-9604, and CJC-1295 for compounding. At the October 2024 meeting, Ipamorelin, kisspeptin-10, and l-theanine were similarly rejected. In both cases, FDA staff dominated the discussion time while nominators and advocates were given limited time to respond. Advocacy organizations publicly criticized the process as structurally biased against compounded substances. However, the July 2026 hearing occurs in a different political environment — with the current administration having publicly committed to restoring compounding access for these substances — which may influence how FDA staff frame their analyses, even if it cannot direct committee votes.

If PCAC votes favorably, how soon could these peptides become legally compoundable?

A favorable PCAC recommendation does not immediately authorize compounding. It initiates the formal rulemaking process: FDA publishes a proposed rule, a public comment period opens, and eventually a final rule is issued adding the substance to the 503A Bulks List. That process typically takes many additional months — often six to eighteen months from the committee vote to final rule, depending on regulatory capacity and workload. Patients and practitioners should plan for this timeline rather than assuming immediate access following a favorable vote in July. The July hearing is the beginning of the process, not the end.

References and Sources

FDA Federal Register Notice, FR Doc. 2026-07361, Docket No. FDA-2025-N-6895. Filed April 15, 2026. Available: federalregister.gov/d/2026-07361
Frieri Levitt. "FDA Peptides: Do Not Compound List Update 2026." Published April 2026. Available: frierlevitt.com/articles/fda-peptides-do-not-compound-list-update-2026/
Boesen & Snow Law. "FDA Advances Peptide Compounding Review: Category 2 Removals Announced and PCAC Hearing Confirmed." Prepared by Courtney M. Sullivan, JD. Published April 15, 2026.
Alliance for Natural Health USA. "FDA Strikes Another Blow Against Compounded Medicines: Peptides Rejected at Latest PCAC Meeting." Published December 2024.
Alliance for Natural Health USA. "FDA Signals Positive Shift on Peptides — But the Fight Is Far From Over." Published 2026.
Sikiric P, et al. "Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications." Curr Neuropharmacol. 2016;14(8):857-865. PMID 24255091
Sikiric P, et al. "Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (IBD)." J Physiol Pharmacol. 2005;56 Suppl 5:23-31. PMID 16188713
Hsieh MJ, et al. "Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation." J Mol Med (Berl). 2017;95(3):323-333. PMID 27995280
Chung L, et al. "Novel application of melanocyte-stimulating hormone and related peptides in inflammatory and fibrotic disorders." J Transl Med. 2013;11:123. (KPV / alpha-MSH fragment context) PMID 23688306
Malinda KM, et al. "Thymosin beta4 accelerates wound healing." J Invest Dermatol. 1999;113(3):364-368. (TB-4 / TB-500 related) PMID 10469336
Lee C, et al. "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance." Cell Metab. 2015;21(3):443-454. PMID 25738459
Khavinson VKh, et al. "Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells." Bull Exp Biol Med. 2004;135 Suppl 7:15-18. PMID 15455795
Semax: Limborska SA, et al. "Analysis of semax activity in the human transcriptome." Mol Genet Genomics. 2003;270(3):216-223. PMID 14517689
21 U.S.C. § 353a — Section 503A of the Federal Food, Drug, and Cosmetic Act. Governs compounding by licensed pharmacists and physicians.
Association for Accessible Medicines / International Academy of Compounding Pharmacists. Comments submitted to PCAC dockets 2023–2024 (public record).

FDA PCAC July 2026 Hearing: What the Panel Will Decide About BPC-157, Semax, Epitalon, and Four More Peptides